|
WO1992013876A1
(en)
|
1991-02-01 |
1992-08-20 |
Coulter Corporation |
METHOD OF PRODUCING F(ab')2 FRAGMENTS OF IMMUNOGLOBULINS
|
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
|
MX336813B
(es)
|
1996-02-09 |
2016-02-02 |
Abbvie Biotechnology Ltd |
Anticuerpos humanos que ligan el tnfa humano.
|
|
NZ507557A
(en)
|
1998-05-06 |
2003-10-31 |
Genentech Inc |
Protein purification by ion exchange chromatography
|
|
CA2817619A1
(en)
|
2001-06-08 |
2002-12-08 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
|
US8658773B2
(en)
|
2011-05-02 |
2014-02-25 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
|
WO2004009776A2
(en)
|
2002-07-19 |
2004-01-29 |
Abbott Biotechnology Ltd. |
TREATMENT OF TNFα RELATED DISORDERS
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
|
US8227241B2
(en)
|
2004-03-12 |
2012-07-24 |
Unigene Laboratories, Inc. |
Bacterial host cell for the direct expression of peptides
|
|
TW201705980A
(zh)
|
2004-04-09 |
2017-02-16 |
艾伯維生物技術有限責任公司 |
用於治療ＴＮＦα相關失調症之多重可變劑量療法
|
|
ES2569409T3
(es)
|
2005-03-08 |
2016-05-10 |
Pfizer Products Inc. |
Composiciones de anticuerpo anti-CTLA-4
|
|
NZ595225A
(en)
|
2005-05-16 |
2013-05-31 |
Abbott Biotech Ltd |
Use of tnf inhibitor for treatment of erosive polyarthritis
|
|
CA2608579C
(en)
|
2005-05-26 |
2019-09-10 |
Cytos Biotechnology Ag |
Scalable fermentation process
|
|
KR101457223B1
(ko)
|
2005-06-07 |
2014-11-04 |
에스바테크 - 어 노바티스 컴파니 엘엘씨 |
ＴＮＦα를 억제하는 안정적이고 가용성인 항체
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
US20070041905A1
(en)
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
|
AR058140A1
(es)
|
2005-10-24 |
2008-01-23 |
Wyeth Corp |
Metodo de produccion proteica utilizando compuestos anti-senescencia
|
|
CN103336129A
(zh)
|
2005-11-01 |
2013-10-02 |
阿布维生物技术有限公司 |
使用生物标志物诊断强直性脊柱炎的方法和组合物
|
|
CN102887955A
(zh)
|
2006-04-05 |
2013-01-23 |
艾博特生物技术有限公司 |
抗体纯化
|
|
WO2008063213A2
(en)
|
2006-04-10 |
2008-05-29 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of psoriatic arthritis
|
|
WO2007120626A2
(en)
|
2006-04-10 |
2007-10-25 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of ankylosing spondylitis
|
|
CA2564435A1
(en)
|
2006-04-10 |
2007-10-10 |
Abbott Biotechnology Ltd. |
Methods for monitoring and treating intestinal disorders
|
|
US9399061B2
(en)
|
2006-04-10 |
2016-07-26 |
Abbvie Biotechnology Ltd |
Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
|
|
EP2666479A3
(en)
|
2006-04-10 |
2014-03-26 |
Abbott Biotechnology Ltd |
Uses and compositions for treatment of juvenile rheumatoid arthritis
|
|
US9605064B2
(en)
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
|
US20080118496A1
(en)
|
2006-04-10 |
2008-05-22 |
Medich John R |
Uses and compositions for treatment of juvenile rheumatoid arthritis
|
|
US7846724B2
(en)
|
2006-04-11 |
2010-12-07 |
Hoffmann-La Roche Inc. |
Method for selecting CHO cell for production of glycosylated antibodies
|
|
US20100021451A1
(en)
|
2006-06-08 |
2010-01-28 |
Wong Robert L |
Uses and compositions for treatment of ankylosing spondylitis
|
|
US20080311043A1
(en)
|
2006-06-08 |
2008-12-18 |
Hoffman Rebecca S |
Uses and compositions for treatment of psoriatic arthritis
|
|
MX2008016335A
(es)
|
2006-06-30 |
2009-01-21 |
Abbott Biotech Ltd |
Dispositivo automatico de inyeccion.
|
|
EP2077325A4
(en)
|
2006-09-11 |
2012-04-11 |
Immuno Biological Lab Co Ltd |
MONOCLONAL ANTIBODY AND ITS USE
|
|
EP2500416A1
(en)
|
2006-09-13 |
2012-09-19 |
Abbott Laboratories |
Cell culture improvements
|
|
AU2007294731B2
(en)
|
2006-09-13 |
2014-04-17 |
Abbvie Inc. |
Cell culture improvements
|
|
US8911964B2
(en)
|
2006-09-13 |
2014-12-16 |
Abbvie Inc. |
Fed-batch method of making human anti-TNF-alpha antibody
|
|
ES2442258T3
(es)
|
2006-10-27 |
2014-02-10 |
Abbvie Biotechnology Ltd |
Anticuerpos cristalinos anti-hTNF alfa
|
|
NZ580378A
(en)
|
2007-03-30 |
2012-11-30 |
Abbott Lab |
Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells
|
|
WO2008136398A1
(ja)
|
2007-04-26 |
2008-11-13 |
Chugai Seiyaku Kabushiki Kaisha |
高濃度アミノ酸含有培地を用いた細胞の培養方法
|
|
WO2008150491A2
(en)
|
2007-05-31 |
2008-12-11 |
Abbott Laboratories |
BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFα INHIBITORS IN AUTOIMMUNE DISORDERS
|
|
WO2008154543A2
(en)
|
2007-06-11 |
2008-12-18 |
Abbott Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis
|
|
UA107557C2
(xx)
*
|
2007-07-06 |
2015-01-26 |
|
Композиція антитіла офатумумабу
|
|
WO2009020654A1
(en)
|
2007-08-08 |
2009-02-12 |
Abbott Laboratories |
Compositions and methods for crystallizing antibodies
|
|
EP2205280B1
(en)
|
2007-09-27 |
2019-09-04 |
Amgen Inc. |
Pharmaceutical formulations
|
|
US8420081B2
(en)
|
2007-11-30 |
2013-04-16 |
Abbvie, Inc. |
Antibody formulations and methods of making same
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
WO2009073805A2
(en)
|
2007-12-04 |
2009-06-11 |
Verdezyne, Inc. |
Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences
|
|
TWI478937B
(zh)
|
2008-01-15 |
2015-04-01 |
Abbvie Inc |
改良之哺乳動物表現載體及其用途
|
|
CA2711984A1
(en)
|
2008-01-15 |
2009-07-23 |
Abbott Gmbh & Co. Kg |
Powdered protein compositions and methods of making same
|
|
ATE460666T1
(de)
|
2008-01-15 |
2010-03-15 |
Univ Utrecht Holding Bv |
Verfahren zur bestimmung der aminosäurensequenz von peptiden
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
JP2011517672A
(ja)
|
2008-03-24 |
2011-06-16 |
アボツト・バイオテクノロジー・リミテツド |
骨損失を治療するための方法及び組成物
|
|
WO2009135181A2
(en)
|
2008-05-02 |
2009-11-05 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
|
MX2011004198A
(es)
|
2008-10-20 |
2011-05-24 |
Abbott Lab |
Anticerpos que unen a il-12 y metodos para purificar los mismos.
|
|
BRPI0920572A8
(pt)
|
2008-10-20 |
2015-10-27 |
Abbott Lab |
Inativação viral durante a purificação dos anticorpos
|
|
NZ592095A
(en)
|
2008-10-20 |
2013-01-25 |
Abbott Lab |
Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
|
|
CA2738243C
(en)
|
2008-10-29 |
2020-09-29 |
Wyeth Llc |
Formulations of single domain antigen binding molecules
|
|
RU2011126338A
(ru)
|
2008-11-28 |
2013-01-10 |
Эбботт Лэборетриз |
Стабильные композиции антител и способы их стабилизации
|
|
CN102348979A
(zh)
|
2009-03-09 |
2012-02-08 |
乔治亚大学研究基金公司 |
胃癌诊断用蛋白标记的鉴定
|
|
US20100278822A1
(en)
|
2009-05-04 |
2010-11-04 |
Abbott Biotechnology, Ltd. |
Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
|
|
US8409838B2
(en)
|
2009-06-02 |
2013-04-02 |
Regeneron Pharmaceuticals, Inc. |
Fucosylation-deficient cells
|
|
CA2763164A1
(en)
|
2009-06-05 |
2010-12-09 |
Momenta Pharmaceuticals, Inc. |
Methods of modulating fucosylation of glycoproteins
|
|
US20110059079A1
(en)
|
2009-09-04 |
2011-03-10 |
Xoma Technology Ltd. |
Antibody Coformulations
|
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
EP3409289B1
(en)
|
2010-02-26 |
2020-09-30 |
Novo Nordisk A/S |
Stable antibody containing compositions
|
|
US9072668B2
(en)
|
2010-03-09 |
2015-07-07 |
Janssen Biotech, Inc. |
Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
|
|
SG10201503899SA
(en)
|
2010-05-18 |
2015-06-29 |
Abbvie Inc |
Apparatus And Process Of Purification Of Proteins
|
|
KR101976853B1
(ko)
|
2010-05-25 |
2019-05-09 |
제넨테크, 인크. |
폴리펩티드의 정제 방법
|
|
EP2575884B1
(en)
|
2010-06-03 |
2018-07-18 |
AbbVie Biotechnology Ltd |
Uses and compositions for treatment of hidradenitis suppurativa (hs)
|
|
JP6010030B2
(ja)
|
2010-09-20 |
2016-10-19 |
アッヴィ・インコーポレイテッド |
疑似移動床クロマトグラフィーを使用する抗体の精製
|
|
US20120258496A1
(en)
|
2010-09-27 |
2012-10-11 |
Boehringer Ingelheim International Gmbh |
Production of low fucose antibodies in h4-ii-e rat cells
|
|
EP2627425A4
(en)
|
2010-10-11 |
2014-11-05 |
Abbvie Inc |
METHODS OF PURIFYING PROTEINS
|
|
US8821865B2
(en)
|
2010-11-11 |
2014-09-02 |
Abbvie Biotechnology Ltd. |
High concentration anti-TNFα antibody liquid formulations
|
|
CN103282509A
(zh)
|
2010-12-28 |
2013-09-04 |
中外制药株式会社 |
动物细胞的培养方法
|
|
US9062106B2
(en)
|
2011-04-27 |
2015-06-23 |
Abbvie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
|
PT2837680T
(pt)
|
2011-07-01 |
2020-04-17 |
Amgen Inc |
Cultura celular de mamífero
|
|
GB201112429D0
(en)
|
2011-07-19 |
2011-08-31 |
Glaxo Group Ltd |
Antigen-binding proteins with increased FcRn binding
|
|
CA2850668A1
(en)
|
2011-10-04 |
2013-04-11 |
Expression Pathology, Inc. |
Srm/mrm assay for the ephrin type-a receptor 2 protein
|
|
PE20141545A1
(es)
|
2011-10-24 |
2014-11-26 |
Abbvie Inc |
Inmunoenlazadores dirigidos contra el tnf
|
|
EP2773439A4
(en)
|
2011-10-31 |
2015-07-01 |
Merck Sharp & Dohme |
CHROMATOGRAPHY METHOD FOR RESOLVING HETEROGENIC ANTIBODY AGGREGATES
|
|
WO2013114165A1
(en)
|
2012-01-30 |
2013-08-08 |
Dr Reddy's Laboratories Limited |
Process of obtaining glycoprotein composition with increased afucosylation content
|
|
WO2013114164A1
(en)
|
2012-01-30 |
2013-08-08 |
Dr. Reddy's Laboratories Limited |
Method for obtaining glycoprotein composition with increased afucosylation content
|
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
|
WO2013186230A1
(en)
|
2012-06-12 |
2013-12-19 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical formulation for a therapeutic antibody
|
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
|
PE20150964A1
(es)
|
2012-09-07 |
2015-07-25 |
Coherus Biosciences Inc |
Formulaciones acuosas estables de adalimumab
|
|
JP5874587B2
(ja)
|
2012-09-10 |
2016-03-02 |
株式会社島津製作所 |
アミノ酸配列解析方法及び装置
|
|
NO2760138T3
(https=)
|
2012-10-01 |
2018-08-04 |
|
|
|
JP2015531244A
(ja)
|
2012-10-15 |
2015-11-02 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
タンパク質を製造するための哺乳動物細胞培養方法
|
|
US9844594B2
(en)
|
2012-12-18 |
2017-12-19 |
Merck Sharp & Dohme Corp. |
Liquid formulations for an anti-TNF α antibody
|
|
EP2938323A2
(en)
|
2012-12-28 |
2015-11-04 |
Abbott Cardiovascular Systems, Inc. |
Therapeutic compositions comprising antibodies
|
|
HK1207960A1
(en)
|
2013-03-12 |
2016-02-19 |
Abbvie Inc. |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
|
US9217168B2
(en)
|
2013-03-14 |
2015-12-22 |
Momenta Pharmaceuticals, Inc. |
Methods of cell culture
|
|
WO2014151901A1
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Improvement of mammalian cell culture performance through surfactant supplementation of feed media
|
|
BR112015017307A2
(pt)
|
2013-03-14 |
2017-11-21 |
Abbvie Inc |
composições de espécies com baixa acidez e métodos para produção e uso das mesmas
|
|
JP6465794B2
(ja)
|
2013-04-25 |
2019-02-06 |
株式会社カネカ |
Ｆａｂ型抗体の分泌量を増大できるＦｄ鎖遺伝子又はＬ鎖遺伝子
|
|
WO2014182658A1
(en)
|
2013-05-06 |
2014-11-13 |
Abbvie Inc. |
Compositions for cell culture and methods of using the same
|
|
TWI596107B
(zh)
|
2013-06-25 |
2017-08-21 |
卡地拉保健有限公司 |
單株抗體之新穎純化方法
|
|
EP3114476A4
(en)
|
2013-10-03 |
2017-11-01 |
Bioanalytix, Inc. |
Mass spectrometry-based method for identifying and maintaining quality control factors during the development and manufacture of a biologic
|
|
EP3057616B1
(en)
|
2013-10-16 |
2020-03-11 |
Outlook Therapeutics, Inc. |
Buffer formulations for enhanced antibody stability
|
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
WO2015140700A1
(en)
|
2014-03-19 |
2015-09-24 |
Dr. Reddy's Laboratories Limited |
Cell culture process
|
|
PT2946765T
(pt)
|
2014-05-23 |
2016-11-10 |
Ares Trading Sa |
Composição farmacêutica líquida
|
|
HUP1400510A1
(hu)
|
2014-10-28 |
2016-05-30 |
Richter Gedeon Nyrt |
Gyógyászati TNFalfa ellenes antitest készítmény
|
|
CN105044222B
(zh)
|
2014-12-19 |
2017-09-12 |
浙江辉肽生命健康科技有限公司 |
生物活性多肽的分析测试和鉴定方法
|
|
WO2016118707A1
(en)
|
2015-01-21 |
2016-07-28 |
Oncobiologics, Inc. |
Modulation of charge variants in a monoclonal antibody composition
|
|
US20180016333A1
(en)
*
|
2015-01-28 |
2018-01-18 |
Mabxience, S.A. |
Pharmaceutical formulations for anti-tnf-alpha antibodies
|
|
CN105779394B
(zh)
|
2015-03-20 |
2020-03-24 |
广东东阳光药业有限公司 |
一种降低抗体酸性峰含量和改良抗体糖型的细胞培养方法
|
|
CA3010600A1
(en)
|
2016-01-06 |
2017-07-13 |
Oncobiologics, Inc. |
Reduction of high molecular weight species, acidic charge species, and fragments in a monoclonal antibody composition
|
|
CN109153716A
(zh)
|
2016-01-06 |
2019-01-04 |
安口生物公司 |
调节单克隆抗体组合物中的非岩藻糖基化物类
|
|
CN109563161A
(zh)
|
2016-02-03 |
2019-04-02 |
安口生物公司 |
用于提高抗体稳定性的缓冲制剂
|
|
AU2017214586A1
(en)
|
2016-02-04 |
2018-08-16 |
Outlook Therapeutics, Inc. |
Methods for identifying and analyzing amino acid sequences of proteins
|